Skip to content
Screener

Medpace Holdings, Inc. MEDP Cash & Equivalents

Cash & Equivalents at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$4.06B-11.7%
Labcorp Holdings logo
Labcorp HoldingsLH
$141.8M-78.1%
IQVIA logo
IQVIAIQV
$1.91B-6.4%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$168.6M+108%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$56.4M+14.3%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$17.24M

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.05B+31.0%
Enterprise value$15.69B+27.0%
P/E32.7×+3.4×
P/S5.8×+0.3×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
(Amounts in thousands)Six Months Ended June 30, 2026Six Months Ended June 30, 2025
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercises19,09426,285
Repurchases of common stock(294,764)(912,815)
Net cash used in financing activities(275,670)(886,530)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH(1,857)5,069
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH5,639(623,106)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period497,049669,436
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period$502,688$46,330

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s cash & equivalents?
Medpace Holdings, Inc. (MEDP) reported cash & equivalents of $502.69M in Q2 2026.
How has Medpace Holdings, Inc.'s cash & equivalents changed year-over-year?
Medpace Holdings, Inc.'s cash & equivalents increased by 985.0% year-over-year, from $46.33M to $502.69M.
What is the long-term trend for Medpace Holdings, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Medpace Holdings, Inc.'s cash & equivalents has grown at a 12.3% compound annual growth rate (CAGR), from $277.77M to $497.05M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Medpace Holdings, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude